Biogen Inc. Stock
Biogen Inc. Stock
Pros and Cons of Biogen Inc. in the next few years
Pros
Cons
Performance of Biogen Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Biogen Inc. | 1.070% | -1.550% | -2.867% | -24.958% | -24.576% | -30.487% | -16.561% |
| Johnson & Johnson | -1.220% | 0.013% | 3.457% | -1.566% | 5.664% | 6.552% | 26.561% |
| Elanco Animal Health Inc. | -1.330% | -0.850% | -1.597% | 18.297% | -3.402% | -52.733% | - |
| Pfizer Inc. | -0.190% | -0.465% | 4.384% | -14.968% | 2.625% | -28.401% | -14.450% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon initial examination, Biogen's financial health appears to be quite stable. The company demonstrates significant total assets backed by a strong shareholder equity. However, it's also essential to dig deeper into the financial landscape of this key player in the pharmaceutical industry to understand its true standing.
Strong Gross Profit: Biogen has consistently reported solid gross profits over the years. This is a positive sign as it indicates effective operations and significant markup on products, a crucial aspect of success within the pharmaceutical industry.
Substantial Assets and Equity: The company boasts noteworthy total assets and shareholder equity. This indicates that Biogen is well-capitalized and has substantial resources at its disposal to facilitate growth and tactical maneuvers in the market.
Comments
News
A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys.
One thing that can help with the treatment of any disease is early detection, and Alzheimer's is no exception to that. And the good news is that in the near future, detecting cases of Alzheimer's
Biogen (BIIB) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
Biogen (NASDAQ: BIIB)Q2 2024 Earnings CallAug 01, 2024, 8:30 a.m. ET
Operator
Source Fool.com
Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy?
Biogen (NASDAQ: BIIB) built itself into a multiple sclerosis (MS) treatment giant over the years -- but as older blockbusters lost exclusivity, growth stalled. And last year, annual revenue dropped